At a glance
ClinicalIndex Comparison RecordN/ACompleted· 359 enrolled
Drug / intervention
Spirivadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics (Patients With Severe Persistent Asthma)
In Brief
An observational study evaluating Spiriva for Asthma. Completed, enrolled 359 participants across 1 site.
Detailed Summary
The safety of Spiriva® 2.5 µg Respimat® 60 puffs (hereinafter referred to as Spiriva® Respimat®) in patients with severe persistent asthma under the real-world use was not confirmed in clinical trials.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesBrazil
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJul 2015
Primary CompletionAug 2017
Study CompletionSep 2017
TodayJul 2026
First PostedJul 3, 2015
Enrollment StartJun 1, 2015
Primary CompletionAug 1, 2017
Study CompletionSep 28, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.0 years ago
Interventions
Spirivadrug
60 puffs